Consequently, the H4R has been recognized as potential anti-inflammatory drug target, and selective antagonists are currently in clinical trials to counteract atopic dermatitis, psoriasis, allergic rhinitis, bronchial allergen challenge, asthma, and rheumatoid arthritis [2]. This evidence concerns the gene HRH4 and asthma.